Recent studies have shown that orlistat may have anticancer properties. The primary mechanism through which orlistat exerts its effect on cancer cells is believed to be its ability to inhibit fatty acid synthase (FAS), an enzyme overexpressed in many types of cancer. FAS is involved in the synthesis of fatty acids, which are crucial for the growth and survival of cancer cells. By inhibiting FAS, orlistat can potentially reduce the proliferation of cancer cells.
